EFFECT OF TREATMENT MODALITY AND MUCOSAL EMERGENCE ANGLE ON PERI-IMPLANT MUCOSITIS TREATMENT OUTCOMES AND BACTERIAL PROFILE: RANDOMIZED CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240512001

Enrollment

Registered

2024-05-12

Start date

2024-05-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peri-implant mucositis peri-implant mucositis peri-implant mucositis treatment mechanical debridement

Interventions

Mechanical debridement with ultrasonic and prophylaxis polishing paste with OHI ,Mechanical debridement with air powder polishing with erytitol/chlorhexidine with OHI

Active Comparator Device,Experimental Device

Ultrasonic,Air-power polishing system

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Participants will be enrolled from patient who received dental implant at Prosthodontic and Esthetic Restorative and Implant Dentistry department, Chulalongkorn University, 2.Age more than 18, 3.Systemically healthy, 4.Non-smoker, 5.Healthy periodontal status or treated periodontitis -Single tooth implant in function more than 1 year and diagnosed with peri-implant mucositis., 6.Mucosal emergence angle of implant prostheses at least 3 points from MB, B, DB, MLi, Li, DLi are more than 30 degrees., 7.Width of keratinized tissue equal or more than 2 mm. around experimental implant , 8.Presence of at least 3 mm soft tissue thickness at implant site, 9.No history of head and neck radiation, 10.Ability and willingness to comply with all study requirements and give informed consent.

Exclusion criteria

Exclusion criteria: 1.Diabetes millitus, 2.Patient requiring antibiotic prophylaxis or receiving antibiotic in the preceding 3 months, 3.Patient receiving corticosteroid or any other medication known to affect the gingiva or the inflammatory reaction eg. antiepileptic drugs, calcium channel antagonist, 4.Patient who pregnant

Design outcomes

Primary

Measure	Time frame
Bleeding Score 6 months Probing,Probing depth 6 months Probing	—

Secondary

Measure	Time frame
Bacterial profile 6 month Bacterial DNA sequencing,PICF 6 months ELISA	—

Countries

Thailand

Contacts

Public ContactNatchaya Thitaphanich

Faculty of Dentistry, Chulalongkorn University

prellethita@gmail.com0894599985

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026